Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15832599 | 0.84 | HRH2 (0.52) | HRH2HRH1PIK3CDKMT2AALDH1A1 | |
| SCHEMBL13995623 | 0.83 | HRH2 (0.51) | HRH2HRH1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL7946318 | 0.83 | HRH2 (0.45) | HRH2HRH1PIK3CDGPR119SMN1; SMN2 | |
| SCHEMBL15599233 | 0.80 | HRH2 (0.45) | HRH2HRH1PIK3CD | |
| SCHEMBL19400534 | 0.80 | HRH2 (0.42) | HRH2HRH1PIK3CDALDH1A1GPR119 | |
| SCHEMBL104620 | 0.80 | USP2 (0.47) | KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL770801 | 0.79 | HRH2 (0.41) | HRH2HRH1PIK3CDALDH1A1GPR119 | |
| SCHEMBL4315666 | 0.78 | PIK3CD (0.46) | PIK3CDALDH1A1SMN1; SMN2TP53TACR1 | |
| SCHEMBL6960632 | 0.78 | PIK3CD (0.66) | PIK3CDALDH1A1SMN1; SMN2TP53 | |
| SCHEMBL10053019 | 0.77 | CYP1A2 (0.48) | HRH2HRH1ALDH1A1GPR119TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | RECURIUM IP HOLDINGS, LLC | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167105-A1 | BCL-2 PROTEIN INHIBITORS | BCL2, BCL2L1, BCL2L2 | HRH2 4556/4885HRH1 4646/4885PIK3CD 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.